基本情報
- 所属
- 自治医科大学 分子病態治療研究センター 遺伝子治療研究部 教授
- 学位
- 医学博士(自治医科大学(JMU))M.D.
- J-GLOBAL ID
- 200901034663759310
- researchmap会員ID
- 1000273320
- 外部リンク
研究キーワード
6研究分野
1経歴
11-
2014年 - 現在
-
2011年 - 2014年
-
2004年 - 2011年
-
1998年 - 2003年
-
1995年 - 1998年
学歴
1-
- 1986年
委員歴
5-
2012年 - 現在
-
2003年
論文
187-
Communications biology 7(1) 642-642 2024年5月27日Alterations in the experience-dependent and autonomous elaboration of neural circuits are assumed to underlie autism spectrum disorder (ASD), though it is unclear what synaptic traits are responsible. Here, utilizing a valproic acid-induced ASD marmoset model, which shares common molecular features with idiopathic ASD, we investigate changes in the structural dynamics of tuft dendrites of upper-layer pyramidal neurons and adjacent axons in the dorsomedial prefrontal cortex through two-photon microscopy. In model marmosets, dendritic spine turnover is upregulated, and spines are generated in clusters and survived more often than in control marmosets. Presynaptic boutons in local axons, but not in commissural long-range axons, demonstrate hyperdynamic turnover in model marmosets, suggesting alterations in projection-specific plasticity. Intriguingly, nasal oxytocin administration attenuates clustered spine emergence in model marmosets. Enhanced clustered spine generation, possibly unique to certain presynaptic partners, may be associated with ASD and be a potential therapeutic target.
-
Molecular neurobiology 2024年4月27日It is established that neurogenesis of dentate gyrus is increased after ischemic insult, although the regulatory mechanisms have not yet been elucidated. In this study, we focused on Ezh2 which suppresses gene expression through catalyzing trimethylation of lysine 27 of histone 3. Male gerbils were injected with adeno-associated virus (AAV) carrying shRNA targeting to Ezh2 into right dentate gyrus 2 weeks prior to forebrain ischemia. One week after ischemia, animals were injected with thymidine analogue to label proliferating cells. Three weeks after ischemia, animals were killed for histological analysis. AAV-mediated knockdown of Ezh2 significantly decreased the ischemia-induced increment of proliferating cells, and the proliferated cells after ischemia showed significantly longer migration from subgranular zone (SGZ), compared to the control group. Furthermore, the number of neural stem cells in SGZ significantly decreased after ischemia with Ezh2 knockdown group. Of note, Ezh2 knockdown did not affect the number of proliferating cells or the migration from SGZ in the non-ischemic condition. Our data showed that, specifically after ischemia, Ezh2 knockdown shifted the balance between self-renewal and differentiation toward differentiation in adult dentate gyrus.
-
Nature Communications 14(1) 2023年11月13日Abstract Although cortical feedback signals are essential for modulating feedforward processing, no feedback error signal across hierarchical cortical areas has been reported. Here, we observed such a signal in the auditory cortex of awake common marmoset during an oddball paradigm to induce auditory duration mismatch negativity. Prediction errors to a deviant tone presentation were generated as offset calcium responses of layer 2/3 neurons in the rostral parabelt (RPB) of higher-order auditory cortex, while responses to non-deviant tones were strongly suppressed. Within several hundred milliseconds, the error signals propagated broadly into layer 1 of the primary auditory cortex (A1) and accumulated locally on top of incoming auditory signals. Blockade of RPB activity prevented deviance detection in A1. Optogenetic activation of RPB following tone presentation nonlinearly enhanced A1 tone response. Thus, the feedback error signal is critical for automatic detection of unpredicted stimuli in physiological auditory processing and may serve as backpropagation-like learning.
-
Journal of molecular and cellular cardiology 180 58-68 2023年7月Sepsis is a life-threatening syndrome, and its associated mortality is increased when cardiac dysfunction and damage (septic cardiomyopathy [SCM]) occur. Although inflammation is involved in the pathophysiology of SCM, the mechanism of how inflammation induces SCM in vivo has remained obscure. NLRP3 inflammasome is a critical component of the innate immune system that activates caspase-1 (Casp1) and causes the maturation of IL-1β and IL-18 as well as the processing of gasdermin D (GSDMD). Here, we investigated the role of the NLRP3 inflammasome in a murine model of lipopolysaccharide (LPS)-induced SCM. LPS injection induced cardiac dysfunction, damage, and lethality, which was significantly prevented in NLRP3-/- mice, compared to wild-type (WT) mice. LPS injection upregulated mRNA levels of inflammatory cytokines (Il6, Tnfa, and Ifng) in the heart, liver, and spleen of WT mice, and this upregulation was prevented in NLRP3-/- mice. LPS injection increased plasma levels of inflammatory cytokines (IL-1β, IL-18, and TNF-α) in WT mice, and this increase was markedly inhibited in NLRP3-/- mice. LPS-induced SCM was also prevented in Casp1/11-/- mice, but not in Casp11mt, IL-1β-/-, IL-1α-/-, or GSDMD-/- mice. Notably, LPS-induced SCM was apparently prevented in IL-1β-/- mice transduced with adeno-associated virus vector expressing IL-18 binding protein (IL-18BP). Furthermore, splenectomy, irradiation, or macrophage depletion alleviated LPS-induced SCM. Our findings demonstrate that the cross-regulation of NLRP3 inflammasome-driven IL-1β and IL-18 contributes to the pathophysiology of SCM and provide new insights into the mechanism underlying the pathogenesis of SCM.
MISC
169-
HUMAN GENE THERAPY 28(12) A24-A25 2017年12月
-
HUMAN GENE THERAPY 28(12) A4-A4 2017年12月
-
MOLECULAR THERAPY 25(5) 58-58 2017年5月
-
HUMAN GENE THERAPY 27(11) A146-A147 2016年11月
-
HUMAN GENE THERAPY 27(11) A45-A45 2016年11月
-
MOLECULAR THERAPY 24 S87-S87 2016年5月
-
MOLECULAR THERAPY 24 S95-S96 2016年5月
-
MOLECULAR THERAPY 24 S158-S159 2016年5月
-
HUMAN GENE THERAPY 26(10) A31-A31 2015年10月
-
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13 S133-S142 2015年6月Hemophilia is considered suitable for gene therapy because it is caused by a single gene abnormality, and therapeutic coagulation factor levels may vary across a broad range. Recent success of hemophilia B gene therapy with an adeno-associated virus (AAV) vector in a clinical trial showed the real prospect that, through gene therapy, a cure for hemophilia may become a reality. However, AAV-mediated gene therapy is not applicable to patients with hemophilia A at present, and neutralizing antibodies against AAV reduce the efficacy of AAV-mediated strategies. Because patients that benefit from AAV treatment (hemophilia B without neutralizing antibodies) are estimated to represent only 15% of total patients with hemophilia, the development of basic technologies for hemophilia A and those that result in higher therapeutic effects are critical. In this review, we present an outline of gene therapy methods for hemophilia, including the transition of technical developments thus far and our novel techniques.
-
MOLECULAR THERAPY 23 S89-S89 2015年5月
-
JOURNAL OF REPRODUCTIVE IMMUNOLOGY 106 14-14 2014年12月
-
HUMAN GENE THERAPY 25(11) A81-A81 2014年11月
-
JOURNAL OF GENE MEDICINE 16(7-8) 249-250 2014年7月
-
JOURNAL OF GENE MEDICINE 16(7-8) 220-220 2014年7月
-
JOURNAL OF GENE MEDICINE 16(7-8) 225-226 2014年7月
-
JOURNAL OF GENE MEDICINE 16(7-8) 237-237 2014年7月
-
JOURNAL OF GENE MEDICINE 16(7-8) 254-254 2014年7月
-
JOURNAL OF GENE MEDICINE 16(7-8) 226-226 2014年7月
-
MOLECULAR THERAPY 22 S165-S166 2014年5月
-
MOLECULAR THERAPY 22 S299-S299 2014年5月
-
自治医科大学紀要 = Jichi Medical University Journal 36 23-31 2014年3月CD28を含むCD19特異的第二世代キメラ抗原受容体( CD19-CAR)による養子免疫遺伝子療法はB細胞腫瘍に対する有望な治療法である。本研究において我々は,CD19-CARに加えIL-21を遺伝子導入したT細胞を作製し,CD19-CAR単独導入T細胞に比し抗腫瘍効果の増強が得られるかを検討した。まず健常者由来の末梢血リンパ球を活性化し,CD19-CAR+IL-21共発現またはCD19-CAR発現レトロウイルスベクターを用いて遺伝子導入した。導入遺伝子の発現はいずれも良好であった。両細胞は同様の増殖を示し,CD19-CAR+IL-21導入細胞でのみIL-21シグナリングの代替マーカーであるSTAT3のリン酸化を認めた。両細胞は表面マーカー上主にCentral memoryあるいはeffector memoryの形質を示し,CD19陽性B細胞株であるRajiに対して細胞傷害性を示し,CD19刺激によりIFN-γを産生した。Rag2-/-γc-/-免疫不全マウスを用いた動物実験では,両細胞はいずれもRajiの増殖を抑制した。IL-21は我々のBリンパ腫モデルでは抗腫瘍効果を修飾せず,CD19-CAR導入T細胞は単独で十分な抗腫瘍効果を発揮する可能性が示された。
-
HUMAN GENE THERAPY 24(12) A36-A36 2013年12月
-
MOLECULAR THERAPY 21 S50-S50 2013年6月
-
第36回日本神経科学大会・第56回日本神経化学会大会・第23回日本神経回路学会大会合同大会. P3-2-242, 京都 2013年6月
-
JOURNAL OF PHYSIOLOGICAL SCIENCES 63 S258-S258 2013年
-
JOURNAL OF PHYSIOLOGICAL SCIENCES 63 S257-S257 2013年
-
HUMAN GENE THERAPY 23(10) A77-A78 2012年10月
-
MOLECULAR THERAPY 20 S253-S253 2012年5月
-
MOLECULAR THERAPY 20 S261-S261 2012年5月
-
MOLECULAR THERAPY 20 S99-S100 2012年5月
-
HUMAN GENE THERAPY 22(10) A49-A50 2011年10月
-
MOVEMENT DISORDERS 26 S120-S120 2011年5月
-
NEUROSCIENCE RESEARCH 71 E163-E163 2011年
-
NEUROSCIENCE RESEARCH 71 E163-E163 2011年
-
NEUROSCIENCE RESEARCH 71 E101-E101 2011年
-
JOURNAL OF GENE MEDICINE 12(12) 1040-1040 2010年12月
-
JOURNAL OF GENE MEDICINE 12(12) 1029-1029 2010年12月
-
JOURNAL OF GENE MEDICINE 12(12) 1024-1024 2010年12月
-
JOURNAL OF GENE MEDICINE 12(12) 1059-1059 2010年12月
-
JOURNAL OF GENE MEDICINE 12(12) 1061-1061 2010年12月
-
JOURNAL OF GENE MEDICINE 12(12) 1049-1049 2010年12月
-
HUMAN GENE THERAPY 21(10) 1420-1420 2010年10月
-
HUMAN GENE THERAPY 21(10) 1367-1367 2010年10月
書籍等出版物
1共同研究・競争的資金等の研究課題
29-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2023年3月